SHANGHAI--(BUSINESS WIRE)--Sep 18, 2026--
Recently, LongHu, the century-old brand under Shanghai Zhonghua Pharmaceutical Co., Ltd., joined forces with Eastday to launch a brand revitalization initiative aimed at bringing new vitality to the time-honored Chinese brand through cross-industry collaborations, creative content and innovative consumer experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918048788/en/
The initiative began at a coffee culture festival, where LongHu attracted widespread attention with its unconventional “LongHu Medicated Oil Coffee.” The creation quickly captured the attention of younger consumers, generating over a million impressions, drawing significant foot traffic and becoming a widely discussed topic across social media platforms.
On May 7, LongHu reached another milestone with the launch event for “Shen Long Huo Hu II,” a co-branded product collaboration between LongHu and Shanghai Shenhua Football Club. The crossover introduced new products that preserve LongHu’s classic herbal heritage while incorporating a younger, more contemporary and stylish expression.
On September 17, the “Shen Long Huo Hu II Energy Recharge Pop-Up Store” opened for a seven-day run, featuring a continuous lineup of activities. Through immersive experiences, interactive check-ins and limited-time experiences, the pop-up gives consumers an opportunity to experience LongHu’s innovative appeal up close.
At the same time, LongHu has partnered with the Shanghai High School Football League to create an AI-powered short drama, connecting the spirit of sports with the spirit of the brand through technology-driven storytelling. Together, these initiatives form part of LongHu’s broader brand revitalization efforts.
From a cup of LongHu Medicated Oil Coffee to a new product launch, and from a pop-up store to an AI-powered short drama, LongHu is building on the wisdom of traditional Chinese herbal culture while embracing cross-industry innovation. Through these initiatives, the brand is presenting overseas markets with a renewed image of a time-honored Chinese brand that is becoming younger and more international. Looking ahead, LongHu will continue to collaborate with partners to bring new vitality to its century-old heritage and expand its presence on the global stage.
Century-Old LongHu, A Legacy of Cool
WASHINGTON (AP) — President Donald Trump is set to announce Friday that all 50 states will join in on a program set to provide most favored nation pricing to some drugs within the Medicaid program, bringing the net price of selected drugs down to prices paid in certain other countries.
The Trump administration claims that Medicaid will save billions on prescription drug costs as a result of the plan, dubbed the Medicaid “GENEROUS” model. Experts say the savings are unclear since the content of the deals isn't public.
Friday's announcement comes as cost-of-living issues are at the forefront of voters’ concerns ahead of the midterm elections in November. In a way to address affordability concerns, Trump has cut deals with pharmaceutical companies so that the cost of some drugs in the U.S. would not be dramatically higher than in other affluent nations.
Last year, Trump signed an executive order instituting a “Most Favored Nations” policy, where the U.S. would commit to paying the same price for medications as the nation that pays the lowest price anywhere in the world.
The White House in May estimated that Trump’s deals with pharmaceutical companies to lower some of their U.S. prescription drug prices to levels charged in other countries could save $529 billion over the next 10 years.
Patients in Medicaid, the state- and federally-funded program for people with low incomes, already pay a nominal co-payment of a few dollars to fill their prescriptions, but lower prices could help state budgets that fund the programs.
The true cost of the claimed savings is unclear since few details of the deals struck by the Trump administration and participating pharmaceutical companies have been made public, making it hard to independently verify the projected savings.
Kathy Hempstead, a senior policy advisor at the Robert Wood Johnson Foundation, told The Associated Press that there is significant pressure on the administration to provide more granular data to justify its cost-savings claims, and that the lack of information creates a barrier to legislative action.
“He is saying Congress should codify all of his MFN arrangements," Hempstead said. “But it’s kind of unreasonable because it’s not clear what Congress would actually do. No one knows what is in these deals.”
She added that there is concern about whether the current administration’s tenure will affect the longevity of these price cuts and whether prices will revert once the administration leaves.
Some want to see more people benefit from lower drug pricing.
JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, said in a statement that Friday's announcement reflects “meaningful progress, but that progress remains incomplete," as millions of Americans not enrolled in government healthcare want lower drug prices.
Drug prices for patients in the U.S. can depend on a number of factors, including the competition a treatment faces and insurance coverage. Most people have coverage through work, the individual insurance market or government programs like Medicaid and Medicare, which shield them from much of the cost.
President Donald Trump speaks during a dinner in the Rose Garden of the White House, Thursday, Sept. 17, 2026, in Washington. (AP Photo/Alex Brandon)
